A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine
| Autor: | Kathrin U. Jansen, Kevin A Ault, Eliav Barr, Judith F. Smith, Gretchen M. Tamms, Anna R. Giuliano, Robert P. Edwards, Deemarie Skulsky, Lee-Lian Kim, Maria Allende, Frank J. Taddeo |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Adult
Time Factors Adolescent viruses Antibodies Viral Virus Genital warts Serology Papillomavirus Vaccines Double-Blind Method medicine Humans Papillomaviridae Cervical cancer General Veterinary General Immunology and Microbiology business.industry Papillomavirus Infections Public Health Environmental and Occupational Health virus diseases Viral Vaccines medicine.disease Virology Vaccination Infectious Diseases Tolerability Immunology Molecular Medicine Papilloma Female business |
| Zdroj: | Vaccine. 22(23-24) |
| ISSN: | 0264-410X |
| Popis: | Human papillomavirus (HPV) infection can cause genital warts and cervical cancer. HPV types 6 and 11 cause >90% of genital wart cases; HPV16 and 18 cause 70% of cervical cancers. A prophylactic HPV (types 6, 11, 16, 18) L1 virus-like particle (VLP) vaccine may substantially reduce the incidence of these lesions. This report describes the results of a phase I study of the HPV18 component of such a vaccine. Forty women were randomized to receive either HPV18 L1 VLP vaccine or placebo. Anti-HPV18 responses were measured using a competitive radioimmunoassay (cRIA). Tolerability was evaluated using vaccination report cards (VRC). The study showed that the HPV18 L1 VLP vaccine was generally well-tolerated and highly immunogenic. Peak anti-HPV18 geometric mean titers (GMT) in vaccines were 60-fold greater than those observed in women following natural HPV18 infection. Further studies of a multivalent HPV L1 VLP vaccines are warranted. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect